From space biology to patient voice to best practices for onboarding, here are highlights of the APPA/MAPS Joint Medical Affairs Summit in Sydney, Australia.
At the MAPS 2022 Global Annual Meeting in New Orleans, we sat down with Medical Affairs leaders in attendance to discuss a range of issues important to the function. Now as we prepare for the MAPS 2023 Global Annual Meeting in Nashville, March 26-29 (early bird registration open until December 31!), join us in looking back at these important opinions. Have a topic you’d like covered at the 2023 meeting? Email MAPS Communications/Marketing Director, Garth Sundem, with your suggestions!
The Medical Affairs Professional Society (MAPS) is honored to announce the appointment of Charlotte Kremer, MD, MBA as the organization’s Chief Strategy Officer in a volunteer capacity, next to her volunteer role as Chair of the Board of Directors.
The Medical Affairs Professional Society (MAPS) and the Industry Pharmacists Organization (IPhO) are pleased to announce an important new strategic collaboration to help advance the careers of student pharmacists interested in the pharmaceutical industry, as well as Fellows and early-stage Industry Pharmacist professionals.
MAPS is excited to announce the appointment of Tamas Koncz, MD, MSc, PhD, Chief Medical Officer for the Inflammation and Immunology Business at Pfizer, to the MAPS Board of Directors.
MAPS is honored to announce the appointment of William (Bill) Sigmund, MD, MHS, EVP and Chief Medical Officer at Becton Dickinson, to the MAPS Board of Directors.
MAPS speaks with co-leads of the Insights Focus Area Working Group (FAWG) about the current state and future directions for Insights in Medical Affairs.
When Robin Winter-Sperry started in the pharmaceutical industry, her mentor, Evelyn was one of the few female managers.
The Medical Affairs Professional Society (MAPS), the premier non-profit global society of Medical Affairs professionals, is honored to announce the election of Mónica de Abadal, VP Medical Excellence, Global Medical Affairs at Ipsen, as MAPS President of the Europe, Middle East and Africa (EMEA) Region. Recently, Dr. de Abadal served as the EMEA 2019 Annual Meeting Co-Chair and was Co-Lead of the Medical Strategy & Launch Excellence Focus Area Working Group. She brings more than 18 years of experience in the pharmaceutical industry.
“Our industry, like many, has seen dramatic change due to the pandemic. My goal as MAPS President of the EMEA Region is to help our members and other Medical Affairs professionals realize the opportunities, the innovation and the responsibilities presented by this time of challenge,” de Abadal says.
Dr. de Abadal has experience in multiple therapeutic areas, including oncology, endocrinology and movement disorders as well as operational and strategic Medical Affairs experience in diverse disciplines of Medical Affairs and product commercialization, such as medical strategy, leading compliance and SOP/policy efforts, quality management systems, data generation, field-based medical teams (MSLs), medical information, safety, medical communications and publications, as well as building and leading local and global teams. Additionally, Dr. de Abadal is currently deeply involved in a medical trasformation exercise that aims to strengthen Ipsen’s medical and scientific profile with a view to bringing measurable improvements to patients’ lives and healthcare professionals’ experiences.
Dr. de Abadal holds a medical degree from the Autonomus University of Barcelona and a postgraduate diploma in pharmaceutical medicine from the University of Barcelona. She trained as a resident in anesthesiology at the Hospital Vall d´Hebron (Barcelona). Additionally, Dr. de Abadal completed the accreditation of her medical degree in the United States and obtained a Master’s in public healthcare administration from the University of San Francisco. She served as a board member in companies specialized in telemedicine and has international Medical Affairs experience in Europe, APAC (Australia) and global positions, including deputy Chief Medical Officer and Global Head of Publications.
“I am honored to see Mónica succeed me in this position. I have experienced the excellence of her work and am confident that Mónica will do a wonderful job elevating the Medical Affairs function within the EMEA Region,” says Danie du Plessis, EVP Medical Affairs at Kyowa Kirin International and outgoing MAPS EMEA Region President.
Dr. de Abadal will guide the growth of the Medical Affairs function in the EMEA region and collaborate with the MAPS leadership to provide direction for the profession as a whole during a time when Medical Affairs is clearly elevated in strategic importance alongside research & development and commercial colleagues from both the biopharmaceutical and medical technology industries.
“We are honored to include Mónica in this highly visible leadership role, where she is able to exemplify the expanding goals of Medical Affairs professionals in Europe, the Middle East and Africa,” says Travis Hege, CEO of MAPS.
The MAPS organization, on behalf of its staff, leadership and members, looks forward to working closely with Dr. de Abadal as Medical Affairs professionals collaborate to advance the organization, the profession, and ultimately, patients who depend on the safety and effectiveness of emerging drugs and technologies.
The Medical Affairs Professional Society (MAPS) is honored to announce the inclusion of Janssen Pharmaceuticals, Inc. in the MAPS Industry Partnership Program (IPP), providing free MAPS membership and training resources for all Janssen Medical Affairs employees globally, as well as opportunities for Janssen leaders to collaborate with peers in other leading biopharmaceutical and medical technology organizations to set strategic direction for the Medical Affairs function.
“Janssen’s partnership with MAPS demonstrates both organizations’ commitment to excellence in Medical Affairs, from placing leaders in a position to influence the future of the profession, to optimizing the competencies of individual team members,” says Travis Hege, MAPS CEO.
Organizations involved in the MAPS IPP become part of a collaborative community of industry leaders and agents for progress in Medical Affairs. Program benefits include participation in regular Executive Consortium meetings for Chief Medical Officers and Global Medical Affairs Heads, priority invitations for senior leaders to participate on expert panels at MAPS Annual Meetings, and full access memberships to MAPS for all Medical Affairs employees in the organization company-wide. Membership also provides access to a community of peers as well as training resources including webinars, articles, best practices forums, eLearning modules, mentorship opportunities, and more.
Janssen joins existing MAPS Industry Partnership Program organizations Astellas, AstraZeneca, Bristol Myers Squibb, Eli Lilly & Co., Lundbeck, Mallinckrodt, Otsuka, Pfizer, Sanofi, Teva and UCB.
“As biopharmaceutical companies seek to deliver new medicines to new patient populations, the role of Medical Affairs is becoming increasingly important. MAPS is excited to grow with our industry partners and with the Medical Affairs function as a whole,” says Hege. “Together we are expanding the capabilities of the function to drive better outcomes for organizations and for patients.”